Edition:
United States

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

20.00EUR
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
€20.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
28,911
52-wk High
€23.88
52-wk Low
€12.96

Latest Key Developments (Source: Significant Developments)

Biotest 9-mth revenue at EUR 377.8 mln
Tuesday, 14 Nov 2017 03:00am EST 

Nov 14 (Reuters) - BIOTEST AG ::DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017.9M REVENUE 377.8 MILLION EUR.‍PAUL-EHRLICH INSTITUTE APPROVES PHASE III TRIAL IN INDICATION OF ACQUIRED FIBRINOGEN DEFICIENCY​.‍EBIT OF CONTINUING OPERATIONS TOTALED EUR -15.7 MILLION IN FIRST THREE QUARTERS OF 2017 AFTER EUR 47.5 MILLION​.9-MONTH ‍EARNINGS AFTER TAXES OF CONTINUING OPERATIONS OF EUR -22.7 MILLION VERSUS EUR 13.3 MILLION YEAR AGO​.  Full Article

Biotest: Tiancheng withdrawal of application of transaction from CFIUS and refiling
Tuesday, 7 Nov 2017 12:51am EST 

Nov 7 (Reuters) - BIOTEST AG ::‍TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG​.‍TIANCHENG WITHDRAWAL OF APPLICATION OF TRANSACTION FROM CFIUS AND REFILING​.BIOTEST - ‍TIANCHENG AND BIOTEST TO WITHDRAW THEIR NOTICE AND TO REFILE NEW APPLICATION WITH REQUEST FOR EXPEDITED REVIEW PERIOD​.  Full Article

Curetis partners with Biotest to support academic PEPPER Pentaglobin Peritonitis trial
Tuesday, 15 Aug 2017 02:23am EDT 

Aug 15 (Reuters) - CURETIS NV ::CURETIS PARTNERS WITH BIOTEST <<>> TO SUPPORT ACADEMIC PEPPER PENTAGLOBIN® PERITONITIS TRIAL WITH UNYVERO IAI APPLICATION.‍TO PROVIDE TESTING SERVICES FOR DIFFERENT SAMPLES FROM UP TO 200 PATIENTS WITH UNYVERO IAI APPLICATION.  Full Article

Biotest H1 result swings to loss of 17.8 million euros
Monday, 14 Aug 2017 03:00am EDT 

Aug 14 (Reuters) - BIOTEST AG ::H1 REVENUE FROM CONTINUING OPERATIONS FELL 11 PERCENT TO 247.1 MILLION EUR.H1 LOSS AFTER TAX -17.8 MILLION EUR VERSUS 7.7 MILLION EUR PROFIT YEAR AGO.‍EBIT OF CONTINUING OPERATIONS AMOUNTED TO EUR -20.2 MILLION IN FIRST HALF OF 2017 COMPARED TO PREVIOUS YEAR'S FIGURE OF EUR 33.3 MILLION​.‍TOTAL EARNINGS AFTER TAXES (EAT) AMOUNTED TO EUR -17.8 MILLION IN FIRST HALF OF 2017 (SAME PERIOD OF PREVIOUS YEAR: EUR 7.7 MILLION)​.NOW FORECASTING SALES AT PREVIOUS YEAR'S LEVEL FOR CONTINUING OPERATIONS IN 2017, AFTER PREVIOUS FORECAST LOW SINGLE-DIGIT PERCENT INCREASE IN SALES​.FY EBIT F'CAST FOR CONTINUING OPERATIONS OF EUR 46-48 MILLION AND CASH FLOW FROM OPERATING ACTIVITIES OF APPROX EUR 40 MILLION HAVE BEEN REDUCED BY AROUND EUR 25 MILLION TO EUR 30 MILLION​.  Full Article

Biotest takes over plasma supplier Cara Plasma s.r.o.
Wednesday, 19 Jul 2017 01:00am EDT 

July 19 (Reuters) - BIOTEST AG ::‍BIOTEST TAKES OVER CARA PLASMA S.R.O. WITH ONE PLASMA COLLECTION CENTRE IN CZECH REPUBLIC​.  Full Article

Tiancheng Pharmaceutical Holdings: offer for Biotest accepted for 89.9 pct of share capital‍​‍​
Friday, 7 Jul 2017 05:32am EDT 

July 7 (Reuters) - BIOTEST AG :TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG - AFTER END OF ADDITIONAL ACCEPTANCE PERIOD OFFER ACCEPTED FOR 17.8 MILLION BIOTEST SHARES, THAT IS 89.9% SHARE CAPITAL‍​‍​.  Full Article

Biotest reaches 2nd milestone in expansion project
Thursday, 22 Jun 2017 01:00am EDT 

June 22 (Reuters) - BIOTEST AG :DGAP-NEWS: BIOTEST AG: BIOTEST REACHES 2ND MILESTONE IN BIOTEST NEXT LEVEL EXPANSION PROJECT.AUTHORITIES GRANT BUILDING APPROVAL.RELOCATION ACTIVITIES OF LABORATORIES AND OFFICES FOR PRODUCTION START IN JUNE.  Full Article

Tiancheng Pharmaceutical Holdings: additional acceptance period for Biotest tender offer
Wednesday, 21 Jun 2017 10:09am EDT 

June 21 (Reuters) - TIANCHENG PHARMACEUTICAL HOLDINGS AG::START OF MANDATORY ADDITIONAL ACCEPTANCE PERIOD FOR BIOTEST AG <<>> TENDER OFFER.  Full Article

Tiancheng Pharmaceutical Holdings says Kreissparkasse Biberach tenders 15.17 pct stake in Biotest
Tuesday, 13 Jun 2017 10:00am EDT 

June 13 (Reuters) - BIOTEST AG :TIANCHENG PHARMACEUTICAL HOLDINGS AG - KREISSPARKASSE BIBERACH TENDERS 15.17% STAKE IN BIOTEST AG INTO TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG'S TENDER OFFER.  Full Article

Biotest ‍sells US therapy business to Adma Biologics, Inc.​
Wednesday, 7 Jun 2017 03:01am EDT 

June 7 (Reuters) - BIOTEST AG ::‍SOLD US THERAPY BUSINESS TO ADMA BIOLOGICS, INC.​.‍RECEIVES 50% MINUS ONE SHARE OF ADMA​.‍RECEIVES ALSO DISTRIBUTION RIGHTS OF SPECIFIED CURRENT PRODUCT AND A RIGHT OF FIRST OFFER FOR DISTRIBUTION OF FUTURE PRODUCTS OF ADMA FOR EUROPE, NEAR AND MIDDLE EAST AND SELECTED ASIAN COUNTRIES​.‍AS PART OF TRANSACTION, BIOTEST HAS CONTRIBUTED EUR11.5 MILLION IN CASH AS WELL AS A EUR14 MILLION LOAN​.  Full Article

BRIEF-Biotest 9-mth revenue at EUR 377.8 mln

* DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017